#ESMO17: Roche extends losing streak with a setback for Zelboraf as Novartis combo surges ahead
MADRID — Roche is on a losing streak.
Hard on the heels of a Phase III flop for a key eye drug, the pharma giant was forced to concede at ESMO that Zelboraf failed to significantly help a group of patients with Stage 3 melanoma. And they acknowledged that flop just as Novartis heralded a success in a Stage 3 group with their combination of Tafinlar and Mekinist.
Roche did note a success on an earlier stage of the disease, with a 46% reduction in recurrence risk recorded in stage IIC-IIIB patients.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters